This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Assessment of lower urinary tract dysfunction in women with multiple sclerosis
1 South Ural State Medical University, Chelyabinsk, Russia
2 National Research Tomsk State University, Tomsk, Russia
3 Medical Rehabilitation Center, Clinical Institute of Brain LLC, Berezovsky, Russia
Correspondence should be addressed: Ekaterina I. Luzanova
Vorovsky, 64, Chelyabinsk, 454092, Russia; ur.xednay@avokihcortse
Funding: the study was conducted as part of the RSF project No. 23-25-10076.
Author contribution: Luzanova EI — clinical assessment, data analysis and interpretation, manuscript writing; Karpova MI, Abramovskikh OS — study design and supervision, approval of the final version of the manuscript; Chetvernina EA, Zotova MA — laboratory tests; Kupriyanov SV — statistical analysis; Bershadskiy AV — data interpretation.
Compliance with ethical standards: the study was approved by the Ethics Committee of the South Ural State Medical University (protocol No. 8 dated 15 September 2023). All subjects submitted the informed consent to enrollment.
- Sakakibara R. Urinary Dysfunction in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Handbook of Neurourology. Singapore. 2023: 737–45.
- Averbeck MA, Mehnert U, Al Mousa RT, Kessler TM. Epidemiology of Neurogenic Lower Urinary Tract Dysfunction. Handbook of Neurourology. Singapore. 2023: 135–40.
- Vecchio M, Chiaramonte R, DI Benedetto P. Management of bladder dysfunction in multiple sclerosis: a systematic review and meta-analysis of studies regarding bladder rehabilitation. Eur J Phys Rehabil Med. 2022; 58 (3): 387–96. DOI: 10.23736/S1973-9087.22.07217-3.
- de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007; 13 (7): 915–28. DOI: 10.1177/1352458506075651.
- Shvarts PG, Popov SV, Zavalishin IA. Patofiziologicheskie i nejrofarmakologicheskie osobennosti terapii hronicheskoj zaderzhki mochi pri rassejannom skleroze. Farmateka. 2017; 6 (339): 51–60. Russian.
- Shvarts PG, Popov SV. Nejrogennaja hronicheskaja zaderzhka mochi u bol'nyh rassejannym sklerozom. Trudnyj pacient. 2018; 16 (6): 61–64. Russian.
- Ozkan B, Demirkesen O, Durak H, Uygun N, Ismailoglu V, Cetinel B. Which factors predict upper urinary tract deterioration in overactive neurogenic bladder dysfunction? Urology. 2005; 66 (1): 99–104. DOI: 10.1016/j.urology.2005.02.009.
- Filippova ES, Bazhenov IV, Zyrianov AV, Borzunov IV, et al. Infekcii mochevyvodjashhih putej u bol'nyh nejrogennym mochevym puzyrem. Consilium Medicum. 2019; 21 (12): 139–44. DOI: 10.26442/20751753.2019.12.190676. Russian.
- Korshunova ES, Yusupova DG, Zimin AA, Pyatnitskaya TM, Zaitsev AB, Yatsko KA, et al. Validacija oprosnika po funkcijam tazovyh organov (Questionnaire on pelvic organ function) u nevrologicheskih bol'nyh v Rossii. Andrologija i genital'naja hirurgija. 2023; 24 (1): 90–99. DOI: 10.17650/2070-9781-2023-24-1-90-99. Russian.
- Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton. Neurosci. 2001; 92 (1–2): 76–85. DOI: 10.1016/S1566-0702(01)00295-8.
- Philippova ES, Bazhenov IV, Volkova LI, Moskvina EY, Turova EL, Popova YV. Russkojazychnaja versija shkaly simptomov nejrogennogo mochevogo puzyrja (NBSS). Urologija. 2018; 6: 5–13. DOI: 10.18565/urology.2018.6.5-13. Russian.
- Ziryanov AV, Bazhenov IV, Philippova ES, Ustinov GS, Turova EL, Toreyev IO, et al. Jepidemiologija i harakter rasstrojstv mocheispuskanija u bol'nyh rassejannym sklerozom. Vestnik urologii. 2020; 8 (2): 29–36. DOI: 10.21886/2308-6424-2020-8-2-29-36. Russian.
- Bientinesi R, Campetella M, Nociti V, Bassi PF, Sacco E. Identification of brain structures involved in lower urinary tract symptoms and sexual dysfunctions in patients with multiple sclerosis. Glob J Med Res. 2021; 21 (2): 42–48.
- Mehnert U, van der Lely S, Seif M, Leitner L, Liechti MD, Michels L. Neuroimaging in Neuro-Urology. Eur Urol Focus. 2020; 6 (5): 826– 37. DOI: 10.1016/j.euf.2019.12.006.
- Kreiter D, Postma AA, Hupperts R, Gerlach O. Hallmarks of spinal cord pathology in multiple sclerosis. J Neurol Sci. 2024; 456: 122846. DOI: 10.1016/j.jns.2023.122846.
- Sastre-Garriga J, Pareto D, Battaglini M, Rocca MA, Ciccarelli O, Enzinger C, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol. 2020; 16 (3): 171–82. DOI: 10.1038/s41582-020-0314-x.
- Vega-P JM, Pascual LA. High-pressure bladder: an underlying factor mediating renal damage in the absence of reflux? BJU Int. 2001; 87 (6): 581–4. DOI: 10.1046/j.1464-410x.2001.00082.x.
- Peyronnet B, Krupp LB, Reynolds WS, Gamé X, Amarenco G, Cornu JN, et al. Nocturia in Patients With Multiple Sclerosis. Rev Urol. 2019; 21 (2–3): 63–73.
- Andersson K-E, Madersbacher H, Altaweel W, Vasudeva P, Igawa Y. Drug Treatment. Handbook of Neurourology. Singapore, 2023; p. 281–315.
- Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014; 33 (Suppl.1): S2–5. DOI: 10.1002/nau.22595.
- Kowalik CG, Cohn JA, Delpe S, Reynolds WS, Kaufman MR, Milam DF, et al. Nocturia: Evaluation and Current Management Strategies. Rev Urol. 2018; 20 (1): 1–6. DOI: 10.3909/riu0797.
- Filippova ES, Bazhenov IV, Moskvina EYu, Zyryanov AV, Borzunov IV. Perevod i aprobacija russkojazychnoj versii oprosnika SF-Qualiveen. Urologicheskie vedomosti. 2019; 9: 100. Russian.
- Kapica-Topczewska K, Tarasiuk J, Chorąży M, Czarnowska A, Brola W, Szczepański M, et al. The epidemiology of comorbidities among multiple sclerosis patients in northeastern Poland. Mult Scler Relat Disord. 2020; 41: 102051. DOI: 10.1016/j.msard.2020.102051.
- Harding K, Zhu F, Alotaibi M, Duggan T, Tremlett H, Kingwell E. Multiple cause of death analysis in multiple sclerosis: A population-based study. Neurology. 2020; 94 (8): e820–e829. DOI: 10.1212/WNL.0000000000008907.
- Medeiros Junior WLG, Demore CC, Mazaro LP, de Souza MFN, Parolin LF, Melo LH, et al. Urinary tract infection in patients with multiple sclerosis: An overview. Mult Scler Relat Disord. 2020; 46: 102462. DOI: 10.1016/j.msard.2020.102462.
- Grebenkina PV, Selkov SA, Kraeva LA, Sokolov DI. Vzaimodejstvie bakterij gruppy ESKAPE i NK-kletok: vzaimnaja reguljacija i rol' v razvitii reproduktivnyh patologij. Infekcija i immunitet. 2023; 13 (4): 609–26. DOI: 10.15789/2220-7619-CBE-15452.
- Miller WR, Arias CA. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol. 2024; 22 (10): 598–616. DOI: 10.1038/s41579-024-01054-w.
- Yarets YuI. Patogennyj potencial bakterij gruppy ESKAPE, vydelennyh iz ran: harakteristika feno- i genotipicheskih markerov i vozmozhnost' ih prakticheskogo primenenija. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2022; 20 (4): 400–13. DOI: 10.25298/2221-8785-2022-20-4-400-413. Russian.
- Phé V, Chartier-Kastler E, Panicker JN Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016; 13 (5): 275–88. DOI: 10.1038/nrurol.2016.53.
- Panicker JN, Fowler CJ. Lower urinary tract dysfunction in patients with multiple sclerosis. Handb Clin Neurol. 2015; 130: 371–81. DOI: 10.1016/B978-0-444-63247-0.00021-3.